Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration...
12 KB (1,231 words) - 17:27, 2 July 2024
Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion...
14 KB (1,671 words) - 12:47, 23 April 2024
below the retinal pigment epithelium. Angiogenesis inhibitors include pegaptanib, ranibizumab and bevacizumab (known by a variety of trade names, such...
7 KB (833 words) - 05:58, 1 January 2024
studied the effectiveness of two anti-VEGF treatments, ranibizumab and pegaptanib, on patients with macular edema caused by CRVO. Participants on both treatment...
16 KB (1,554 words) - 21:17, 30 October 2023
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
68 KB (5,996 words) - 02:41, 17 July 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
149 KB (15,717 words) - 04:09, 1 August 2024
evidence supports the use of anti-VEGF antibodies, such as bevacizumab or pegaptanib which seems to improve outcomes when used in conjunction with laser therapy...
19 KB (2,059 words) - 20:05, 20 July 2024
Commercial products and companies based on aptamers include the drug Macugen (pegaptanib) and the clinical diagnostic company SomaLogic. The International Society...
60 KB (6,559 words) - 14:38, 19 June 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
17 KB (1,489 words) - 05:47, 7 April 2024
injection) – Pharmacologic stress agent for myocardial perfusion scan Macugen (pegaptanib sodium) – Anti-angiogenic – marketed with Gilead Sciences in the US and...
27 KB (2,449 words) - 21:35, 29 June 2024